Pooja Solanki Mishra

Pooja Solanki Mishra

Auto-generated profile, based on publicly available information

Pooja Solanki Mishra

Mahatma Gandhi Memorial Medical College and M.Y. Hospital, Indore, M.P., India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2023 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
HHHani Hamade
Hani Hamade
AJAhmad Jabri
Ahmad Jabri
PMPooja Mishra
Pooja Mishra
MBMuhammad Umer Butt
Muhammad Umer Butt
SSSherin Sallam
Sherin Sallam
SKSaima Karim
Saima Karim
Introduction: Female patients, patients from racial minorities, and patient with low socioeconomic status have been noted to have less access to catheter ablation for atrial fibrillation.Methods: This is a cross-sectional, retrospective study using a large population database (Explorys) to evaluate the gender, racial and socioeconomic differences in access of catheter ablation therapy in patient with atrial fibrillation.Results: A total of 2.2 million patients were identified as having atrial fibrillation and 62,760 underwent ablation. Females had ablation in 2.1% of cases while males received ablation in 3.4% of cases. Caucasians had ablation in 3.3% of cases, African Americans in 1.5% of cases and other minorities in 1.2% of cases. Individuals on medicaid underwent ablation in 1.6% of cases, individuals on medicare and private insurance had higher rates (2.8 and 2.9%, respectively). Logistic regression showed that female patients (OR 0.608, CI 0.597–0.618, p < 0.0001), patients who are African American (OR 0.483, CI 0.465–0.502, p < 0.0001), or from other racial minorities (OR 0.343, CI 0.332–0.355, p < 0.0001) were less likely to undergo ablation. Patient with medicare (OR 1.444, CI 1.37–1.522, p < 0.0001) and private insurance (OR 1.572, CI 1.491–1.658, p < 0.0001) were more likely to undergo ablation.Conclusion: Female gender, racial minorities, low socioeconomic status are all associated with lower rates of catheter ablation in management of atrial fibrillation.

7 May 2024 in Asian Journal of Pharmaceutical and Clinical Research
Verified
Journal Article
Open access
PDF file
PMPooja Solanki Mishra
Pooja Solanki Mishra
SMSapna More
Sapna More
KGKamayani Gupta
Kamayani Gupta
DRDeepti Rastogi
Deepti Rastogi
NVNarlapati Vignan
Narlapati Vignan
Objectives: The objectives of the study are to assess the knowledge about self-medication and factors influencing the use of self-medication among 2nd year medical, paramedical, and non-medical students. Methods: A cross-sectional, multicenter study was conducted among 520 students of medical, physiotherapy, nursing, and engineering courses. Students were given a pre-structured questionnaire in e form/physical forms. The responses were collected and analyzed using descriptive statistics. Results: It was found that 63% of students followed self-medication, among which 41% took medication from a chemist. Analgesic and antipyretic (31.8%) followed by cough and cold (23%) medication were the most common group for self-medication. Conclusion: Self-medication is seen more commonly in medical students, especially the hosteller group. The most common reason for self-medication is the easy availability of drugs and the absence of strict regulations.

1 May 2024 in International Journal of Pharmacy and Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
AMAkash Mishra
Akash Mishra
PMPooja Solanki Mishra
Pooja Solanki Mishra
AKAnjali Kushwah
Anjali Kushwah
KGKamayani Gupta
Kamayani Gupta
Objective: Our study aimed to evaluate the cost percent variation and cost ratio of different brands of oral anti-migraine drugs available in Indian market. Methods: The cost of various commonly used oral anti-migraine drugs were taken from the latest issue of Current Index of Medical Specialities January 2022, Drug Today January-April 2022 and 1 mg online site. Cost percent variation and Cost ratio were calculated. Results: A total of 7 single anti-migraine drugs and 9 Fixed-Dose Combinations (FDCs) showed a wide range of cost variation. The highest cost percent variation of 433% was seen in Sumatriptan 50 mg with a cost ratio of 5.33, whereas Amitriptyline 10 mg showed the lowest cost percent variation of 47.9% with a cost ratio of 1.47. Among FDCs Naproxen 500 mg+Sumatriptan 85 mg showed the highest cost per cent variation of 400% with a cost ratio of 5.25 and Propranolol 40 mg+Flunarizine 10 mg showed the lowest cost per cent variation of 46.56% with a cost ratio of 1.46. Conclusion: Our study showed a wide variation in the cost of oral anti-migraine drugs available in the Indian market, which provides insight to the healthcare professional and gives Drug Price Control Order (DPCO) authorities to minimize the financial burden and improve patient compliance.

5 August 2022 in Pharmacology and Clinical Pharmacy Research
Verified
Journal Article
Open access
PDF file
PHPallav Hetawal
Pallav Hetawal
SMSapna More
Sapna More
KGKamayani Gupta
Kamayani Gupta
PMPooja S. Mishra
Pooja S. Mishra
Fluoroquinolones are broad-spectrum antibacterial for treating respiratory tract, intra-abdominal, urinary tract, pelvic, joint, bone, soft tissue, and skin infections. The economic burden on patients affects compliance in developing countries like India. Therefore, the prices of drugs should be controlled effectively. Hence, this study was done to assess the cost variation of branded oral fluoroquinolones available in India compared with generic counterparts. The maximum and minimum cost of oral fluoroquinolones (INR per 10 tablets) of the same strength and dosage form manufactured by different companies was obtained from Drug Today April to July 2021 Volume 1, MIMS, and 1mg.com. The cost ratio and the percentage cost variation of individual drug brands were calculated. Prices of generic fluoroquinolones from the Jan Aushadhi scheme (JAS) were compared with branded drugs. Of 11 different oral fluoroquinolones, levofloxacin 500 mg had the highest percentage variation of 11.100%, and three formulations marketed by a few manufacturers have a percentage reduction of less than 100%. Of 23 different combinations available as 33 different dosages, the highest cost variations were observed in Norfloxacin 400 mg plus tinidazole 600 mg combination (1317%). When compared, some generic fluoroquinolones available under JAS were not cheaper than the minimum cost of their branded counterparts. Wide variation in the cost of the different brands of the same oral fluoroquinolones manufactured by other companies was observed. This adds to the economic burden for the patients. Hence, stakeholders should aim to decrease the cost variation among different brands while maintaining therapeutic efficacy

1 January 2026 in Postępy Psychiatrii i Neurologii
Verified
Journal Article
Open access
PDF file
THTasneem Hussain
Tasneem Hussain
KGKrishna Gupta
Krishna Gupta
ATAshutosh Tiwari
Ashutosh Tiwari
PMPooja S. Mishra
Pooja S. Mishra
Lafora body disease (LBD) is a rare autosomal recessive progressive myoclonic epilepsy characterized by neurodegene-ration due to an intracellular accumulation of poorly branched polyglucosan inclusions. Effective pharmacological management remains challenging due to the risk of drug-induced exacerbation of symptoms and adverse interactions. We present the case of an 18-year-old male with intractable seizures, myoclonus, and cognitive regression. Electroencephalogram showed frequent generalized polyspike discharges, and histopathology confirmed Lafora bodies. The patient was initially prescribed a broad polypharmacy regimen including sodium valproate, carbamazepine, phenytoin, and phenobarbitone – leading to detrimental pharmacokinetic and pharmacodynamic interactions, worsening his neurological status. A stepwise revision with withdrawal of contraindicated agents and rational introduction of levetiracetam, clobazam, and perampanel improved seizure control and alertness. This case highlights the hazards of unstructured polypharmacy in LBD and stresses the need for individualized pharmacotherapy. Novel disease-modifying options like metformin, targeting glycogen metabolism, offer future therapeutic potential in altering disease trajectory.